Skip to content

The impact of the 5A nursing model on pain in patients with postherpetic neuralgia

The impact of the 5A nursing model on pain in patients with postherpetic neuralgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104499
Enrollment
Unknown
Registered
2025-06-18
Start date
2024-11-02
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

Control group:The control group received routine clinical care, including The control group received routine nursing care, which included: (1) condition monitoring: closely observing changes in the pa
(2) administering appropriate analgesic medications to patients according to medical orders. At the same time, carefully observing the efficacy and adverse reactions of the medications, and promptly a
(3) skin care, maintaining the cleanliness of the patients skin
(4) providing information and education about postherpetic neuralgia to patients to enhance their self-management abilities.
Experimental group:On the basis of the control group, the observation group implemented an additional 5A nursing model, which includes five key steps: assessment, advice, agreement, assist, and arrang

Sponsors

Zunyi Medical University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients must have a clear history of herpes zoster and have been diagnosed with postherpetic neuralgia if they still experience pain in the original lesion area one month after the rash has healed; 2. The patient voluntarily joined this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Other causes of pain (acute and chronic pain patients caused by migraine, tension headaches, peripheral neuropathy, osteoarthritis, and other reasons); 2. Individuals with mental illnesses or serious illnesses (such as severe infections, heart, lung, liver, and kidney dysfunction, tumors, immune deficiencies, and other serious illnesses).

Design outcomes

Primary

MeasureTime frame
Biochemical Parameters;Pain Assessment;

Countries

China

Contacts

Public ContactYi Xi

Zunyi Medical University Affiliated Hospital

yixi198707@163.com+86 150 8509 5390

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 19, 2026